Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000315066-26-001172
Filing Date
2026-05-06
Accepted
2026-05-06 11:13:07
Documents
2
X0202

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 6605
2 exhibit99.txt EX-99 2627
  Complete submission text file 0000315066-26-001172.txt   11027
Mailing Address 245 SUMMER STREET BOSTON MA 02210
Business Address 245 SUMMER STREET BOSTON MA 02210 6175706339
FMR LLC (Filed by) CIK: 0000315066 (see all company filings)

EIN.: 043532603 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 0000

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8547
Denali Therapeutics Inc. (Subject) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90223 | Film No.: 26946701
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)